Pennsylvania news: Personalized treatment for deadly blood and bone marrow cancer
WFMZ-TV in Allentown, Pennsylvania recently highlighted the University of Cincinnati's John Byrd and the Beat AML study testing personalized treatment for patients with acute myelogenous leukemia.
“Although it has one name there are probably 15, 20 different types of AML. Before, when people were diagnosed with AML, they would come in and everybody would be treated the same way,” said Byrd, MD, a University of Cincinnati Cancer Center researcher, chair of the Department of Internal Medicine at the UC College of Medicine and the chief medical officer of the Beat AML study.
Using genetic sequencing, researchers are identifying what drives each patient's disease and personalizing treatments accordingly.
“Once a medicine gets approved in one indication, it can potentially be applied to a lot of other types of cancers that have that same mutation, but might be in a different part of the body,” Byrd said.
The Beat AML trial is unique because it a master trial studying multiple drugs at the same time.
Featured photo at top of Erin Hertlein, PhD, left, and John Byrd, MD, working in the lab. Photo/UC Foundation.
Related Stories
Colorado silica dust trial could change the way industry does business
May 17, 2026
Betsy Malloy, Andrew Katsanis Professor of Law, at the University of Cincinnati, spoke with Bloomberg Law about how a Colorado trial could change the way the stone fabrication industry does business.
Three years, countless stories
May 15, 2026
UC's Klekamp Law celebrates its 193rd Hooding with stories from graduates reflecting on their paths through the college.
Driven by curiosity, guided by care
May 14, 2026
Max Wilson, a University of Cincinnati College of Allied Health Sciences health sciences major on the pre-physician assistant track, found his path expanding beyond the classroom and into hands-on research focused on human performance and patient care.